Overcoming negative predictions of microRNA expressions to gemcitabine response with FOLFIRINOX in advanced pancreatic cancer patients.
FOLFIRINOX
gemcitabine
miRNA
pancreatic cancer
Journal
Future science OA
ISSN: 2056-5623
Titre abrégé: Future Sci OA
Pays: England
ID NLM: 101665030
Informations de publication
Date de publication:
30 Nov 2020
30 Nov 2020
Historique:
entrez:
13
1
2021
pubmed:
14
1
2021
medline:
14
1
2021
Statut:
epublish
Résumé
FOLFIRINOX is superior to gemcitabine in patients with pancreatic cancer, but this regimen is associated with toxicity and biomarkers for response are warranted. MicroRNAs can mediate drug resistance and could provide predictive information. Altered expressions of several microRNAs including miR-21-5p, miR-10b-5p and miR-34a-5p have been previously linked to a worse response to gemcitabine. We investigated the influence of expression levels in tumor tissue of those three microRNAs on outcome to FOLFIRINOX. Twenty-nine patients with sufficient formalin-fixed paraffin-embedded tumor tissue were identified. There was no significant association between high and low expression groups for these three microRNA. We conclude that polychemotherapy combination can overcome intrinsic negative prognostic factors.
Identifiants
pubmed: 33437513
doi: 10.2144/fsoa-2020-0128
pmc: PMC7787156
doi:
Types de publication
Journal Article
Langues
eng
Pagination
FSO644Informations de copyright
© 2020 Konstantin Schlick.
Déclaration de conflit d'intérêts
Financial & competing interests disclosure This research was funded by the Reiner-Brettenthaler grant 2013 from the Medical Association of Salzburg. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.
Références
Mod Pathol. 2012 Dec;25(12):1609-22
pubmed: 22878649
PLoS One. 2010 May 14;5(5):e10630
pubmed: 20498843
Pancreas. 2013 Jan;42(1):67-71
pubmed: 22850622
Presse Med. 2019 Mar;48(3 Pt 2):e113-e123
pubmed: 30878335
Hepatobiliary Surg Nutr. 2015 Feb;4(1):24-33
pubmed: 25713802
Nat Rev Cancer. 2006 Apr;6(4):259-69
pubmed: 16557279
Cancer Treat Rev. 2014 Jun;40(5):595-604
pubmed: 24286642
Pancreas. 2012 Nov;41(8):1280-4
pubmed: 22836856
N Engl J Med. 2018 Dec 20;379(25):2395-2406
pubmed: 30575490
PLoS One. 2009 Aug 28;4(8):e6816
pubmed: 19714243
Nat Rev Cancer. 2006 Nov;6(11):857-66
pubmed: 17060945
N Engl J Med. 2013 Oct 31;369(18):1691-703
pubmed: 24131140
Cancer. 1995 Nov 1;76(9):1671-7
pubmed: 8635074
Am J Clin Oncol. 1982 Dec;5(6):649-55
pubmed: 7165009
Cancer. 1981 Jan 1;47(1):207-14
pubmed: 7459811
Pancreas. 2009 Oct;38(7):e190-9
pubmed: 19730150
Int J Cancer. 2010 Jan 1;126(1):73-80
pubmed: 19551852
Clin Chem. 2008 Oct;54(10):1716-24
pubmed: 18719196
FEBS J. 2018 Oct;285(20):3695-3716
pubmed: 29688631
Biochim Biophys Acta Rev Cancer. 2018 Aug;1870(1):67-75
pubmed: 29702208
N Engl J Med. 2011 May 12;364(19):1817-25
pubmed: 21561347
Trends Mol Med. 2011 Nov;17(11):650-8
pubmed: 21802991
CA Cancer J Clin. 2019 Sep;69(5):363-385
pubmed: 31184787
Cancer Res. 2014 Jun 1;74(11):2913-21
pubmed: 24840647
Cancer Res. 2006 Aug 1;66(15):7390-4
pubmed: 16885332
Mol Oncol. 2013 Jun;7(3):334-45
pubmed: 23177026
Ann Oncol. 2015 Sep;26 Suppl 5:v56-68
pubmed: 26314780
Br J Cancer. 2013 Feb 5;108(2):361-9
pubmed: 23329235
Oncogene. 2014 Jan 23;33(4):514-24
pubmed: 23334332
Biochem Pharmacol. 2010 Mar 15;79(6):817-24
pubmed: 19883630
Oncogene. 2007 Jun 28;26(30):4442-52
pubmed: 17237814
Ann Oncol. 2013 Mar;24(3):734-41
pubmed: 23139258
Ann Surg Oncol. 2010 Dec;17(12):3120-8
pubmed: 20652642
Mol Cancer. 2010 Jun 28;9:169
pubmed: 20579395
Cancer Res. 2010 Jun 1;70(11):4528-38
pubmed: 20460539
Clin Cancer Res. 2011 Sep 1;17(17):5812-21
pubmed: 21652542
JAMA. 2007 May 2;297(17):1901-8
pubmed: 17473300
Ann Surg. 2020 Jun;271(6):1137-1147
pubmed: 30394883
Cancer Med. 2016 Apr;5(4):693-702
pubmed: 26864640
Clin Cancer Res. 2012 Jan 15;18(2):534-45
pubmed: 22114136